Get the Stockscreener App
2.59
3.00%
-0.08
After Hours:
2.59
Xenetic Biosciences Inc stock is traded at $2.59, with a volume of 3,098.
It is down -3.00% in the last 24 hours and down -36.21% over the past month.
See More
Previous Close:
$2.67
Open:
$2.66
24h Volume:
3,098
Relative Volume:
0.45
Market Cap:
$3.99M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-0.9418
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
-20.55%
1M Performance:
-36.21%
6M Performance:
-42.83%
1Y Performance:
-43.94%
1-Day Range:
$2.46
$2.67
1-Week Range:
$2.26
$3.43
52-Week Range:
$2.26
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.59 | 3.99M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Analyzing Takeda Pharmaceutical (NYSE:TAK) and Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Biosciences stock hits 52-week low at $2.7 By Investing.com - Investing.com South Africa
Xenetic Biosciences stock hits 52-week low at $2.7 - Investing.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 46.4% - Defense World
Xenetic partners with PeriNess for cancer study in Israel By Investing.com - Investing.com South Africa
Xenetic partners with PeriNess for cancer study in Israel - Investing.com Australia
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - standard-journal.com
Breakthrough DNase Treatment Takes Aim at Aggressive Childhood Cancers in New Trial - Stock Titan
Research Analysts Set Expectations for XBIO FY2025 Earnings - Defense World
Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright - Defense World
Analysts Offer Predictions for XBIO Q1 Earnings - Defense World
Xenetic Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results - guardonline.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Expands By 29.2% - Defense World
Xenetic Biosciences Strengthens Cancer Research Pipeline While Maintaining $6.2M Cash Position - Stock Titan
Xenetic Biosciences, Inc. SEC 10-K Report - TradingView
XENETIC BIOSCIENCES Earnings Preview: Recent $XBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Xenetic Biosciences Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire
Breakthrough: New DNase I Treatment Supercharges CAR T Cell Cancer Therapy Success - StockTitan
Xenetic Biosciences (XBIO) Expected to Announce Earnings on Thursday - Defense World
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Armenian Reporter
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Milton Daily Standard
Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Decline in Short Interest - Armenian Reporter
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 21.4% in January - Defense World
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 1,920.0% in January - Defense World
Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology - ACCESS Newswire
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event - ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire
XBIOW (Xenetic Biosciences) Operating Income : $-4.36 Mil (TTM As of Sep. 2024) - GuruFocus.com
XBIOW (Xenetic Biosciences) Dividend Yield % : 0.00% (As of Jan. 13, 2025) - GuruFocus.com
XBIOW (Xenetic Biosciences) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8% - Defense World
Xenetic Biosciences Advances Revolutionary DNase Cancer Treatment Platform with UVA Partnership - StockTitan
Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 - StockTitan
Xenetic Biosciences shareholders elect directors, approve auditor By Investing.com - Investing.com UK
Xenetic and PeriNess partner for cancer treatment trials By Investing.com - Investing.com Canada
Xenetic and PeriNess partner for cancer treatment trials - Investing.com
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - AccessWire
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):